Should intravesical Bacillus Calmette-Guérin be employed in transplant recipients with bladder carcinoma?: Short communication
Journal
Transplant Infectious Disease
Journal Volume
12
Journal Issue
4
Pages
358-362
Date Issued
2010
Author(s)
Singh N.
Abstract
Bacillus Calmette-Gu?rin (BCG) exerts its antitumor activity through induction of pro-inflammatory cytokines, while immunosuppressive agents prevent organ rejection by suppressing pro-inflammatory and promoting anti-inflammatory responses. Thus, in the setting of transplant populations, the use of intravesical BCG for bladder cancer has the possibility of either promoting allograft rejection or being rendered ineffective by the action of immunosuppressive agents that block pro-inflammatory responses. We discuss the potential immunologic interactions between BCG and immunosuppression, and review relevant outcomes in renal transplant recipients with bladder cancer receiving intravesical BCG. ? 2010 John Wiley & Sons A/S.
SDGs
Other Subjects
basiliximab; BCG vaccine; corticosteroid; cytokine; daclizumab; epirubicin; everolimus; immunosuppressive agent; isoniazid; mammalian target of rapamycin; mitomycin; mycophenolic acid 2 morpholinoethyl ester; rapamycin; tacrolimus; antineoplastic activity; bladder carcinoma; cystitis; cytokine production; drug hypersensitivity; drug mechanism; epididymitis; graft recipient; graft rejection; human; immunosuppressive treatment; kidney abscess; kidney graft; mycobacteriosis; outcomes research; priority journal; prostatitis; review; treatment indication; Administration, Intravesical; Adult; Aged; BCG Vaccine; Carcinoma, Transitional Cell; Cytokines; Female; Graft Rejection; Humans; Immunosuppression; Kidney Transplantation; Male; Middle Aged; Mycobacterium bovis; Th1 Cells; Treatment Outcome; Urinary Bladder Neoplasms
Type
review